|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
358,710 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
O'connor Daniel |
Chief Executive Officer |
|
2016-01-29 |
4 |
S |
$6.88 |
$60,668 |
D/D |
(8,818) |
313,394 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-01-29 |
4 |
D |
$6.82 |
$4,692 |
D/D |
(688) |
322,212 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-01-29 |
4 |
A |
$6.82 |
$8,866 |
D/D |
1,300 |
322,900 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-01-29 |
4 |
S |
$6.88 |
$21,321 |
D/D |
(3,099) |
130,557 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-01-29 |
4 |
D |
$6.82 |
$1,023 |
D/D |
(150) |
133,656 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-01-29 |
4 |
A |
$6.82 |
$2,196 |
D/D |
322 |
133,806 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-01-29 |
4 |
D |
$6.82 |
$539 |
D/D |
(79) |
95,017 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-01-29 |
4 |
A |
$6.82 |
$1,937 |
D/D |
284 |
95,096 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2015-12-31 |
4 |
D |
$10.06 |
$412 |
D/D |
(41) |
166,271 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2015-12-31 |
4 |
A |
$10.06 |
$1,962 |
D/D |
195 |
166,312 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-12-31 |
4 |
D |
$10.06 |
$734 |
D/D |
(73) |
120,309 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-12-31 |
4 |
A |
$10.06 |
$2,938 |
D/D |
292 |
120,382 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-12-31 |
4 |
D |
$10.06 |
$594 |
D/D |
(59) |
94,812 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-12-31 |
4 |
A |
$10.06 |
$2,465 |
D/D |
245 |
94,871 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2015-12-31 |
4 |
D |
$10.06 |
$2,978 |
D/D |
(296) |
332,953 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2015-12-31 |
4 |
A |
$10.06 |
$10,674 |
D/D |
1,061 |
333,249 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-12-31 |
4 |
D |
$10.06 |
$473 |
D/D |
(47) |
133,484 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-12-31 |
4 |
A |
$10.06 |
$2,938 |
D/D |
292 |
133,531 |
|
- |
|
Berman Richard J |
Director |
|
2015-12-17 |
4 |
S |
$12.39 |
$177,573 |
D/D |
(14,332) |
84,430 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-11-30 |
4 |
D |
$12.07 |
$266 |
D/D |
(22) |
133,240 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2015-11-30 |
4 |
A |
$12.07 |
$1,967 |
D/D |
163 |
133,262 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-11-30 |
4 |
D |
$12.07 |
$266 |
D/D |
(22) |
94,631 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2015-11-30 |
4 |
A |
$12.07 |
$1,642 |
D/D |
136 |
94,653 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-11-30 |
4 |
D |
$12.07 |
$398 |
D/D |
(33) |
120,091 |
|
- |
|
Mayes Gregory T. |
Chief Operating Officer |
|
2015-11-30 |
4 |
A |
$12.07 |
$1,967 |
D/D |
163 |
120,124 |
|
- |
|
454 Records found
|
|
Page 9 of 19 |
|
|